Paenibacillus dendritiformis causes destructive meningitis in infants. This emerging pathogen poses a serious threat. Recent reports highlight severe cases in the US.
Doctors first identified it in preterm babies. One case involved a 2-month-old girl born at 26 weeks. She developed respiratory distress and seizures suddenly. Blood and CSF cultures grew the bacterium. Brain imaging showed rapid progression. It included hydrocephalus, abscesses, and encephalomalacia.
Another infant, a 37-day-old boy, faced similar devastation. He needed a ventriculoperitoneal shunt. Despite treatment, he developed seizures and feeding issues. Tragically, he died at 11 months.
Initially, labs identified it as Paenibacillus thiaminolyticus using MALDI-TOF MS. However, whole-genome sequencing confirmed Paenibacillus dendritiformis. The bacterium carries virulence factors. These include type IV pilus genes for invasion. It also has multiple β-lactamases and vancomycin resistance genes. Plus, it produces thiaminase 1, which depletes thiamine locally.
Infections often strike NICU babies or preterm infants. Transmission remains unclear. Soil microbiome links exist, but direct exposure seems unlikely. Some cases associate with rainfall or water sources.
Standard empiric antibiotics fail frequently. Many regimens prove inadequate against this bug. Treatment requires prolonged courses. Meropenem infusions work in some cases. Doctors add vancomycin or rifampin often. Neurosurgical intervention becomes essential. Shunts drain hydrocephalus. Abscess drainage helps too.
Early thiamine supplementation shows promise. It counters the thiaminase effect. This may reduce brain damage partially.
Clinicians now raise awareness urgently. Young infants face high risk of neurologic sequelae. Survival often comes with disabilities. Early recognition saves lives. Aggressive management limits devastation.
Overall, Paenibacillus dendritiformis emerges as a critical concern. It demands vigilance in neonatal care. Research continues to uncover modes of spread. Better diagnostics and targeted therapies will follow.